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Introduction 
 
Skin cancer is a growing problem in Ireland. It is by far the commonest cancer accounting for 26% of all malignancies.1 
Melanoma incidence and mortality have more than doubled between 1994 and 2013 and it is now the 5th commonest 
cancer in men and women.2 Because of this, melanoma treatment is deemed to be best managed by specialist skin 
cancer services in secondary care.3 Optimal service management of non-melanoma skin cancer is less clear-cut. 
Excision biopsies of non-melanoma skin cancer could be conducted by General Practitioners rather than in secondary 
care.  This would have the advantages of rapid, apparently effective treatment, satisfying the General Practitioner and 
patient alike. Several studies have assessed adequacy of excision as an index of efficiency in primary care with varying 
results.4-7 Diagnostic accuracy has not previously been assessed and would have a bearing in terms of the number of 
unnecessary excisions performed. 
Abstract 
  
Aim 
To compare the relative efficiencies of skin excisions in primary and secondary care. 
 
Methods 
We compared the benign: malignant ratio for specimens referred by General Practice, General Surgery and the Skin 
Cancer Service to the regional pathology laboratory over one month. We used cost minimization analysis to compare 
the relative efficiencies of the services. 
 
Results 
620 excisions were received: 139 from General Practice, 118 from General Surgery and 363 from the Skin Cancer 
Service. The number (%) of malignant lesions was 13 (9.4%) from General Practice, 18 (15.2%) from General Surgery 
and 137 (37.7%) from the Skin Cancer Service. Excision was cheaper in General Practice at €84.58 as compared to 
€97.49 in the hospital day surgical unit. However, the cost per malignant lesion excised was €1779.80 in general 
practice versus €381.78 in the Skin Cancer Service.  
 
Conclusion 
Our results indicate that moving skin cancer treatment to General Practice may result in an excess of benign excisions 
and therefore be both less efficient and less cost effective. 
We used the pathology database at Cork University Hospital, which processes all specimens for the Cork region, to 
compare the relative efficiencies of the various services in the management of all skin cancers. To examine cost 
effectiveness a cost minimisation analysis was performed. 
 
Methods  
The pathology database at Cork University Hospital was searched to extract all skin biopsy specimens received during 
the month of October 2016. Diagnostic punch and incision biopsies were excluded. Benign and malignant excision 
biopsies were assessed. The source of the biopsy was classified according to origin into the following groups: General 
Practice, General Surgery or the Hospital Skin Cancer Service (Dermatology, Plastic surgery, specialist skin cancer 
surgery). Specimens were grouped as follows: invasive melanoma, in situ melanoma, benign pigmented lesions, non-
melanoma skin cancer, SCC in situ (Bowen’s disease) and other benign lesions.  
To examine cost effectiveness, a cost minimization analysis was performed. This is a type of economic evaluation 
wherein the two alternatives have equivalent outcomes and so the service that delivers the outcome at the least cost 
is considered to be the more cost effective.8  Here, then, the outcome is a malignant lesion and the cost of a biopsy in 
hospital was compared to that in general practice using micro costing techniques (see Table 1).9,10 The GP and Nurse 
time, direct and indirect administration work, practice management, day-to-day running costs etc were assessed as 
outlined previously.11 This was complemented by consultation with a local General Practitioner, Hospital Human 
Resources and Service Planning departments. 
 
Table 1. Cost of Biopsy 
 Cost of Biopsy in Primary Care Minutes Rate Cost 
Locum GP 30  1.84  55.20 
Practice Nurse  20  0.54  10.80 
Equipment  
  
18.58 
Total 
  
84.58 
    
Cost of Biopsy in Secondary Care 
   
Nurse (x2)  30 0.52 30.08 
Registrar 30 0.95 28.00 
Clerical Grade 3  22 0.35 7.57 
Clerical Grade 4 10 0.41 4.10 
Supplies & Pharmacy 
  
27.74 
Total 
  
97.49 
 
 
Results 
In October 2016, 620 skin excision biopsies were received in the Pathology Dept. at CUH: 139 from general practice, 
118 from general surgery and 363 from the skin cancer service. The number (percentage) of malignant lesions was 13 
(9%) from general practice, 18 (15%) from general surgery and 137 (37%) from the skin cancer service (table 2).  
 
 
Table 2. Number (percentage) of malignant and benign lesions excised in General practice and secondary care. 
 
 General Practice General Surgery Skin Cancer Service 
Malignant 13 (9%) 18 (15%) 137 (38%) 
Benign 126 (91%) 100 (85%) 226 (62%) 
Total 139 118 363 
 
One in situ melanoma was received from General Practice, 4 invasive melanomas were received from General Surgery 
and 10 invasive melanomas plus 13 in situ melanomas from the Skin Cancer Service (table 3). Four SCCs and 8 BCCs 
were received from General Practice, 6 SCC plus 8 BCCs from General Surgery, and 43 SCC plus 71 BCCs from the Skin 
Cancer Service.  
 
 
Table 3. Diagnosed malignancies from General Practice, General Surgery and the Skin Cancer Service. 
 
 General Practice General Surgery Skin Cancer Service 
Invasive melanoma 0 4 10 
In-situ melanoma 1 0 13 
BCC 8 8 71 
SCC 4 6 43 
Benign 126 100 226 
 
 
126(91%) benign skin lesions were excised in General Practice, 100(85%) by General Surgery and 226(62%) by the Skin 
Cancer Service. 
 
Biopsy Costings 
Resources used in an excision biopsy in primary care included each piece of equipment as well as the costs of both the 
GP and practice nurses’ time - 30 minutes and 20 minutes respecively.11, 12 The estimated rate per minute of a Principal 
GP and Practice Nurse was €1.84 and €0.54, taking into account additions for PRSI, pensions and overheads. Thus, the 
cost in primary care was estimated to be €84.58 (See Table 1).  
The cost of providing a biopsy in a hospital Day Surgery setting was calculated on the basis that the average biopsy 
takes 30 minutes and involves two nurses (30 minutes x 2 = 60 minutes) and a registrar doctor (30 minutes), as well 
as clerical costs and overheads, supplies and pharmacy consumables. Using the mid-point wage rates and accounting 
for PRSI, the cost of nursing is €0.52 per minute and a registrar doctor was €0.95 per minutes. Clerical costs, including 
hospital chart preparation, lab paperwork and filing were costed for a Grade 3 Clerical Officer rate of €0.35 and typing 
was calculated for a Grade 4 Clerical rate of €0.41 per minute. The total cost of a biopsy in secondary care was 
calculated at (See Table 1). 
The cost of processing each specimen in the pathology lab was estimated at €93.40 (processing €50, pathologist review 
€43.40). This cost would be identical regardless of whether the biopsy originated in primary or secondary care.                                                                                          
Cost Minimisation Analysis 
To examine cost effectiveness a cost minimisation analysis was utilized; wherein the two alternatives have equivalent 
outcomes and so the service that delivers the outcome at the least cost is considered to be the more cost effective.8  
Here the cost of performing a biopsy in General Practice was less expensive than in secondary care (€84.58 v €97.49). 
Adding the cost of processing a pathology specimen, the cost of biopsy in General Practice was €177.98 v €190.89 in 
the Skin Cancer Service. However, the ratio of benign to malignant lesions was over 9:1 in General Practice versus just 
under 2:1 in the Skin Cancer Service. That is to say, for every 10 biopsies in General Practice on average only one will 
be malignant, where as in the Skin Cancer Service on average five out of every 10 would be malignant. Therefore the 
cost per malignancy excised in General Practice was €1,779.80 versus €381.78 in the Skin Cancer Service.  
 
Discussion 
Skin cancer is a growing problem Worldwide. In Ireland, the most recent annual incidence of melanoma (2016-18) is 
1110 and for non-melanoma skin cancer 10,816.1 The incidence of melanoma is rising faster than most other cancers 
and doubling every 15 years. This is putting a strain on healthcare resources in primary and secondary care. Because 
of the potential for metastases and associated mortality, the NCCP recommends that all suspect pigmented lesions 
should be referred to secondary care for assessment by Dermatology or Plastic Surgery at the regional skin cancer 
service.3   
The optimum approach for non-melanoma skin cancer is less certain. A number of issues arise in deciding who should 
excise these lesions. The issue of adequate excision has been explored by several authors in the UK, Australia and 
Holland.4-7 Maguire and Maguire7 also examined the results of surgery, over 1 year, at their practice in Dublin. While 
some authors found problems with excision margin, many did not and the overall impression is that low risk lesions 
could easily be excised in General Practice.  
The second issue relates to diagnostic accuracy. Koehling et al.13 reported that 9 out of 10 lesions suspected of 
malignancy in General Practice were in fact benign. More recently Ahmadi et al.14 appeared to show better diagnostic 
accuracy in Dutch General Practice. Diagnostic accuracy is important because it has cost and manpower implications. 
If too many benign lesions are excised, apart from the impact on patients, this will result in increased cost and 
unnecessary extra workload for an already stretched healthcare system.  
Our study was designed to look at the existing practice of General Practitioners in relation to skin lesion excision in 
our region. We found that there was an excess of benign lesions excised. While, it is not possible to determine whether 
this was due to diagnostic difficulty, many seborrhoeic keratoses were excised in the general practice cohort. These 
lesions would not normally be excised unless there was diagnostic uncertainty as they are generally only of cosmetic 
concern and often best left untreated. If bleeding or catching in clothing, they can be treated with liquid nitrogen, 
which is widely available in Primary Care. While a greater percentage of benign lesions (cysts, skin tags and warts) 
were excised by General practitioners, the fact that almost 50% of lesions were pigmented and a significant number 
of malignancies were excised also suggests that the lesions were excised because of concern about malignancy. 
Our results indicate that movement of excision of non-melanoma skin cancers to the community would be costly. 
Based on the ratio of benign to malignant lesions excised, we estimate that the cost to the health service would 
increase over 4 fold (from €381.78 to €1779.80). The extra cost per non-melanoma skin cancer excised would be 
almost €1400. Given that almost 9000 non-melanoma skin cancers were excised nationally in 2016, this would have 
significant budgetary implications. It could be argued that, with improved training of General Practitioners in the 
recognition of benign lesions, the ratio of benign to malignant excisions might be improved. However, the experience 
with the use of General Practioners with special interest in the UK has been disappointing and not cost effective. 15 
 
In the absence of an Irish reference cost list, as is available in the UK, a micro-costing analysis was performed here. 
This is the most precise method of costing, as advocated by Drummond et al 8. In conducting the micro-costing expert 
opinion was elicited and local cost estimates were applied, thus while the best available the estimates are subject to 
uncertainty. Also, compared to the UK costs for general minor surgery in primary and secondary care settings the 
estimates in this study are conservative.  
In summary, we have found that an excess of benign skin lesions are excised in General Practice in our region. Cost 
minimisation analysis indicates that the skin cancer service in secondary care is more cost effective. 
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